tetano
Editor, Senior Moderator
PLoS One
. 2023 Sep 26;18(9):e0288006.
doi: 10.1371/journal.pone.0288006. eCollection 2023. Production and characterization of a chimeric antigen, based on nucleocapsid of SARS-CoV-2 fused to the extracellular domain of human CD154 in HEK-293 cells as a vaccine candidate against COVID-19
Thailin Lao[SUP] 1 [/SUP], Ileanet Avalos[SUP] 1 [/SUP], Elsa María Rodríguez[SUP] 1 [/SUP], Yasser Zamora[SUP] 1 [/SUP], Alianet Rodriguez[SUP] 1 [/SUP], Ailyn Ramón[SUP] 2 [/SUP], Yanitza Alvarez[SUP] 1 [/SUP], Ania Cabrales[SUP] 3 [/SUP], Ivan Andújar[SUP] 3 [/SUP], Luis Javier González[SUP] 3 [/SUP], Pedro Puente[SUP] 4 [/SUP], Cristina García[SUP] 5 [/SUP], Leonardo Gómez[SUP] 5 [/SUP], Rodolfo Valdés[SUP] 5 [/SUP], Mario Pablo Estrada[SUP] 1 [/SUP], Yamila Carpio[SUP] 1 [/SUP]
Affiliations
Despite that more than one hundred vaccines against SARS-CoV-2 have been developed and that some of them were evaluated in clinical trials, the latest results revealed that these vaccines still face great challenges. Among the components of the virus, the N-protein constitutes an attractive target for a subunit vaccine because it is the most abundant, highly conserved and immunogenic protein. In the present work, a chimeric protein (N-CD protein) was constructed by the fusion of the N-protein to the extracellular domain of human CD154 as the molecular adjuvant. HEK-293 cells were transduced with lentiviral vector bearing the N-CD gene and polyclonal cell populations were obtained. The N-CD protein was purified from cell culture supernatant and further characterized by several techniques. Immunogenicity studies in mice and non-human primates showed the N-CD protein induced high IgG titers in both models after two doses. Moreover, overall health monitoring of non-human primates demonstrated that animals were healthy during 228 days after first immunization. Data obtained support further investigation in order to develop this chimeric protein as vaccine candidate against COVID-19 and other coronavirus diseases.
. 2023 Sep 26;18(9):e0288006.
doi: 10.1371/journal.pone.0288006. eCollection 2023. Production and characterization of a chimeric antigen, based on nucleocapsid of SARS-CoV-2 fused to the extracellular domain of human CD154 in HEK-293 cells as a vaccine candidate against COVID-19
Thailin Lao[SUP] 1 [/SUP], Ileanet Avalos[SUP] 1 [/SUP], Elsa María Rodríguez[SUP] 1 [/SUP], Yasser Zamora[SUP] 1 [/SUP], Alianet Rodriguez[SUP] 1 [/SUP], Ailyn Ramón[SUP] 2 [/SUP], Yanitza Alvarez[SUP] 1 [/SUP], Ania Cabrales[SUP] 3 [/SUP], Ivan Andújar[SUP] 3 [/SUP], Luis Javier González[SUP] 3 [/SUP], Pedro Puente[SUP] 4 [/SUP], Cristina García[SUP] 5 [/SUP], Leonardo Gómez[SUP] 5 [/SUP], Rodolfo Valdés[SUP] 5 [/SUP], Mario Pablo Estrada[SUP] 1 [/SUP], Yamila Carpio[SUP] 1 [/SUP]
Affiliations
- PMID: 37751460
- DOI: 10.1371/journal.pone.0288006
Despite that more than one hundred vaccines against SARS-CoV-2 have been developed and that some of them were evaluated in clinical trials, the latest results revealed that these vaccines still face great challenges. Among the components of the virus, the N-protein constitutes an attractive target for a subunit vaccine because it is the most abundant, highly conserved and immunogenic protein. In the present work, a chimeric protein (N-CD protein) was constructed by the fusion of the N-protein to the extracellular domain of human CD154 as the molecular adjuvant. HEK-293 cells were transduced with lentiviral vector bearing the N-CD gene and polyclonal cell populations were obtained. The N-CD protein was purified from cell culture supernatant and further characterized by several techniques. Immunogenicity studies in mice and non-human primates showed the N-CD protein induced high IgG titers in both models after two doses. Moreover, overall health monitoring of non-human primates demonstrated that animals were healthy during 228 days after first immunization. Data obtained support further investigation in order to develop this chimeric protein as vaccine candidate against COVID-19 and other coronavirus diseases.